A new system for profiling drug-induced calcium signal perturbation in human embryonic stem cell-derived cardiomyocytes

Journal of Biomolecular Screening

Volumn 20, Issue 3, 2015, Pages 330-340

  Lewis, Kimberley J ^a   Silvester, Nicole C ^a   Barberini Jammaers, Steven ^a   Mason, Sammy A ^a   Marsh, Sarah A ^a   Lipka, Magdalena ^a   George, Christopher H ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

calcium signaling; cardiac; cell imaging; drug discovery; human; stem cells

Indexed keywords

ASTEMIZOLE; CISAPRIDE; FLECAINIDE; NADOLOL; SOTALOL; THIORIDAZINE; TROPONIN T; VALDECOXIB; ANTIARRHYTHMIC AGENT;

ACTION POTENTIAL DURATION; ANALYTIC METHOD; ARRHYTHMOGENESIS; ARTICLE; CALCIUM SIGNALING; CELL DEATH; CELL DENSITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; EMBRYONIC STEM CELL; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMBRANE STEADY POTENTIAL; PRIORITY JOURNAL; SPATIOTEMPORAL ANALYSIS; SYNCHRONIZATION, AMPLITUDE, LENGTH, AND VARIABILITY OF OSCILLATION; CARDIAC MUSCLE CELL; CELL CULTURE; CELL LINE; CLUSTER ANALYSIS; CYTOLOGY; DRUG DEVELOPMENT; DRUG EFFECTS; MEMBRANE POTENTIAL; METABOLISM; PRECLINICAL STUDY; PROCEDURES;

ANTI-ARRHYTHMIA AGENTS; CALCIUM SIGNALING; CELL LINE; CELLS, CULTURED; CLUSTER ANALYSIS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; EMBRYONIC STEM CELLS; HUMANS; MEMBRANE POTENTIALS; MYOCYTES, CARDIAC; TROPONIN T;

EID: 84923327914     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057114557232     Document Type: Article

References (30)

1. Silvester N. C., George C. H.. Searching for New Cardiovascular Drugs: Towards Improved Systems for Drug Screening?. Expert Opin. Drug Discov. 2011 ; 6: 1155-1170
2. Moller C., Slack M.. Impact of New Technologies for Cellular Screening along the Drug Value Chain. Drug Disc. Today. 2010 ; 15: 384-390
3. Pouton C., Haynes J. M.. Embryonic Stem Cells as a Source of Models for Drug Discovery. Nat. Rev. Drug Disc. 2007 ; 6: 605-616
4. Braam S. R., Tertoolen L., van de Stolpe A., et al. Prediction of Drug-Induced Cardiotoxicity Using Human Embryonic Stem Cell-Derived Cardiomyocytes. Stem Cell Res. 2010 ; 4: 107-116
5. Dick E., Rajamohan D., Ronksley J., et al. Evaluating the Utility of Cardiomyocytes from Human Pluripotent Stem Cells for Drug Screening. Biochem. Soc. Trans. 2010 ; 38: 1037-1045
6. George C. H., Parthimos D., Silvester N. C.. A Network-Oriented Perspective on Cardiac Calcium Signaling. Am. J. Physiol. Cell Physiol. 2012 ; 303: C897 - C910
7. George C. H., Barberini-Jammaers S. R., Muller C. T.. Refocussing Therapeutic Strategies for Cardiac Arrhythmias: Defining Viable Molecular Targets to Restore Cardiac Ion Flux. Expert Opin. Ther. Patents. 2008 ; 18: 1-19
8. George C. H., Lai F. A.. Developing New Anti-Arrhythmics: Clues from the Molecular Basis of Cardiac Ryanodine Receptor (RyR2) Ca2+-Release Channel Dysfunction. Curr. Pharm. Des. 2007 ; 13: 3195-3211
9. Li S., Chen G., Li R. A.. Calcium Signalling of Human Pluripotent Stem Cell-Derived Cardiomyocytes. J. Physiol. 2013 ; 591: 5279-5290
10. George C. H., Higgs G. V., Lai F. A.. Ryanodine Receptor Mutations Associated with Stress-Induced Ventricular Tachycardia Mediate Increased Calcium Release in Stimulated Cardiomyocytes. Circ. Res. 2003 ; 93: 531-540
11. George C. H., Higgs G. V., Mackrill J. J., et al. Dysregulated Ryanodine Receptors Mediate Cellular Toxicity: Restoration of Normal Phenotype by FKBP12.6. J. Biol. Chem. 2003 ; 278: 28856-28864
12. George C. H., Rogers S. A., Bertrand B. M. A., et al. Alternative Splicing of Ryanodine Receptors Modulates Cardiomyocyte Ca2+ Signaling and Susceptibility to Apoptosis. Circ. Res. 2007 ; 100: 874-883
13. Clements M., Thomas N.. High-Throughput Multi-Parameter Profiling of Electrophysiological Drug Effects in Human Embryonic Stem Cell Derived Cardiomyocytes Using Multi-Electrode Arrays. Toxicol. Sci. 2014 ; 140: 445-461
14. Uhlen P.. Spectral Analysis of Calcium Oscillations. Sci STKE 2004. 2004 ;:
15. George C. H., Silvester N. C., Barberini-Jammaers S. R.. Method and System for Analyzing Calcium Transients in Coupled Cells.. 2010 ;:
16. Redfern W. S., Carlsson L., Davis A. S., et al. Relationships between Preclinical Cardiac Electrophysiology, Clinical QT Interval Prolongation and Torsade de Pointes for a Broad Range of Drugs: Evidence for a Provisional Safety Margin in Drug Development. Cardiovasc. Res. 2003 ; 58: 32-45
17. Darpo B.. Spectrum of Drugs Prolonging QT Interval and the Incidence of Torsades de Pointes. Eur. Heart J. 2001 ; 3: K70 - K80
18. Glassman A. H., Bigger J. T.. Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death. Am. J. Psychiatry. 2001 ; 158: 1774-1782
19. Zhang J., Ding E. L., Song Y.. Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-Analysis of Randomized Trials. JAMA. 2006 ; 296: 1619-1632
20. Fedorov V. V., Lozinsky I. T., Sosunov E. A., et al. Application of Blebbistatin as an Excitation-Contraction Uncoupler for Electophysiologic Study of Rat and Rabbit Hearts. Heart Rhythm. 2007 ; 4: 619-626
21. Liu J., Fu J.-D., Siu C.-W., et al. Functional Sarcoplasmic Reticulum for Calcium Handling of Human Embryonic Stem Cell-Derived Cardiomyocytes: Insights for Driven Maturation. Stem Cells. 2007 ; 25: 3038-3044
22. Uesugi M., Ojima A., Taniguchi T., et al. Low-Density Plating Is Sufficient to Induce Cardiac Hypertrophy and Electrical Remodelling in Highly Purified Human iPS Cell-Derived Cardiomyocytes. J. Pharmacol. Toxicol. Meth. 2014 ; 69: 177-188
23. Otsuji T. G., Minami I., Kurose Y., et al. Progressive Maturation in Contracting Cardiomyocytes Derived from Human Embryonic Stem Cells: Qualitative Effects on Electrophysiological Responses to Drugs. Stem Cell Res. 2010 ; 4: 201-213
24. Pyrko P., Kardosh A., Liu Y.-T., et al. Calcium-Activated Endoplasmic Reticulum Stress as a Major Component of Tumor Cell Death Induced by 2,5-Dimethyl-Celecoxib, a Non-Coxib Analogue of Celecoxib. Mol. Cancer Ther. 2007 ; 6: 1262-1275
25. Guo L., Coyle L., Abrams R. M. C., et al. Refining the Human iPSC - Cardiomyocyte Arrhythmic Risk Assessment Model. Toxicol. Sci. 2013 ; 136: 581-594
26. Harris K., Aylott M., Cui Y., et al. Comparison of Electrophysiological Data from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes to Functional Preclinical Safety Assays. Toxicol. Sci. 2013 ; 134: 412-426
27. Guo L., Abrams R. M. C., Babiarz J. E., et al. Estimating the Risk of Drug-Induced Proarrhythmia Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Toxicol. Sci. 2011 ; 123: 281-289
28. Chaitman B. R.. Ranolazine for the Treatment of Chronic Angina and Potential Use in Other Cardiovascular Conditions. Circulation. 2006 ; 113: 2462-2472
29. Jerling M.. Clinical Pharmacokinetics of Ranolazine. Clin. Pharmacokinet. 2006 ; 45: 469-491
30. Lee P., Klos M., Bollensdorff C., et al. Simultaneous Voltage and Calcium Mapping of Genetically Purified Human Induced Pluripotent Stem Cell-Derived Cardiac Myocyte Monolayers. Circ. Res. 2012 ; 110: 1556-1563